here is the link u wanted
well once again you prove to be right on the money. All it does is climb, only a moron would short this stock now! But you are right imo, much more upside coming.
1st as NEOP, now daily as the new company called "NAVB". Only question is: how far will it climb into the sky--VERY VERY far, nothing to stop this baby's run up! NO NEWS EXCEPT GOOD NEWS, DAILY CLIMBING but the BEST is yet to come!!!!!!
The bashers have nothing to work with. The stock keeps rising. Plenty of cash in the bank. Three great drugs. Strong management. A major catalyst in a couple months and all the analysts rating it strong buy with 9 dollar targets.
Did everyone read about NAVB's new alzheimers diagnostic agent??
Wall street is all over NAVB as the next DNDN
Upgrade with better info on AZD
NAVB executives believe the stock is going higher
ANOTHER drug buy in! WOW!
If I was short I would be covering fast too!
The Wall street pros love NAVB. Why is that??
Morgan Joseph TriArtisan initiated coverage of Neoprobe on May 13, 2011. Click here for a copy of their initial NEOP Analysis report. Morgan Joseph rates NEOP a "Buy" with a 12-month price target from $9.00.
October 27, 2011: Update Report
Rodman & Renshaw initiated coverage of Neoprobe on February 14, 2011 with a "Market Outperform" rating and a price target of $6. Click here for Rodman & Renshaw's initial coverage report.
October 27, 2011: Update Report
WBB Securities initiated coverage of Neoprobe on May 8, 2009. Click here for a copy of WBB Securities initial NEOP Analysis report. WBB Securities rates NEOP a "Strong Buy" and upgraded its 12-month price target from $8.50 to $9.00 on May 26, 2011.
November 21, 2011: Update Report
LifeSci Advisors initiated coverage on March 8, 2011. LifeSci Advisors is compensated to prepare the report, but does not offer an opinion on the future price of NEOP stock and has no investment rating on the company. Click here for the Initial Coverage Report.'
November 4, 2011 - Update Report
Life Tech Capital odman & Renshaw initiated coverage of Neoprobe on February 14, 2011 with a Market Outperform rating and a price target of $6. Click here for Rodman & Renshaw's initial coverage report.iniininitiated coverage on March 25, 2011 with a "Strong Speculative Buy" rating and a target of $5.75. Click here for their Initial Coverage Report.
November 17, 2011 - Update Report
Ladenburg Thalmann initiated coverage on April 21, 2011 with a "Buy" rating and a target of $5.75. Click here for their Initial Investment Report.
October 27, 2011 - Update Note w/$6.25 price target
JMP Securities initiated coverage on May 5, 2011 with a "Market Outperform" rating and has a target of $8.00. Click here for their Initial Investment Report.
December 2, 2011 - Update Note
Taglich Brothers Re-initiated coverage November 18, 2011 raising their opinion from "Neutral" to a "Speculative Buy" rating and a target of $3.00. Click here for their Investment Report.
Zacks Investment Research rates NEOP as a "Neutral".
TheStreet.com raised NEOP from a "Sell" to a "Hold" rating on April 18th, 2011 (you must be a client to review their research).
Why are the shorts covering??
Impressive performance. I wouldn't fight this trend if I was short.